Pharmacological Treatment of Peptic Ulcer Disease
Peptic ulcer disease (PUD) is an upper gastrointestinal (GI) disorder with complex etiology, which is a growing major concern worldwide. The pathophysiology of PUD is relatively well understood, hence there are several specific treatment options for this disorder aiming at various pharmacological targets located in the GI tract. In this chapter we provide an overview on pharmacological targets as well as drugs that are currently available for PUD therapy with regard to the etiology of the disease. We discuss their mechanisms of action, evidences for their effectiveness emerging from clinical trials as well as virtues and drawbacks of the most commonly prescribed medications. Furthermore, we highlight the practical aspects of the use of drugs in PUD, such as dosing regimens, resistance issues, possible adverse events, and contraindications.
KeywordsPeptic ulcer Gastric ulcer Non-steroidal anti-inflammatory drugs Proton pump inhibitor Prostaglandin Histamine receptor
Complementary and alternative medicine
Prostaglandin type E receptor
G protein-coupled receptor
- H+/K+ ATPase
Histamine type 2 receptors
Non-steroidal anti-inflammatory drugs
Proton pump inhibitor
Peptic ulcer disease
Tumor necrosis factor α
The authors are supported by the Medical University of Lodz [502-03/1-156-04/502-14-140 to MS and #502-03/1-156-04/502-14-299 to PM] and the National Science Centre [#UMO-2015/16/T/NZ7/00031 and #UMO-2013/11/N/NZ7/02354 to MS and #UMO-2016/21/N/NZ5/01932 to PM]. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
The authors have nothing to disclose.
- 18.Pouw RE, Bredenoord AJ. Mistakes in the use of PPIs and how to avoid them. UEG Edu. 2017;17:15–17.Google Scholar
- 20.Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20 mg rabeprazole compared with 20 mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5 years. Aliment Pharmacol Ther. 2003;17(3):343–51.CrossRefPubMedGoogle Scholar